Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04624672 · ClinicalTrials.gov registry record · Phase 4
Treatment of GLP-1 for Diabetic Bariatric Patients
A Phase 4 study, sponsored by Geisinger Clinic.
- Terminated
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT04624672 is a Phase 4 study that was terminated before completion, run by Geisinger Clinic. The registered enrollment target is 3 participants.
The verdict
NCT04624672, a Phase 4 study, was terminated before completion, sponsored by Geisinger Clinic.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study is for patients that are diabetic, and require insulin for glycemic control, and going through the bariatric surgery process. This is a prospective study that is trying to determine if the introduction of a semaglutide increases the remission rates of diabetes post-operatively.
Interventions
- DRUG Placebo
- DRUG Semaglutide (1 Mg Dose)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-08-25 |
| Est. Completion | 2022-08-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04624672
The ClinicalTrials.gov registry entry for NCT04624672 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Geisinger Clinic, which has 107 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04624672 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04624672 about?
NCT04624672 is a clinical study titled "Treatment of GLP-1 for Diabetic Bariatric Patients". This study is for patients that are diabetic, and require insulin for glycemic control, and going through the bariatric surgery process. This is a prospective study that is trying to determine if the introduction of a semaglutide increases the remission rates of diabetes post-operatively.
What is the current status of trial NCT04624672?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2021-08-25. Estimated completion is 2022-08-17.
What interventions are being tested in trial NCT04624672?
The interventions under investigation include: Placebo (DRUG), Semaglutide (1 Mg Dose) (DRUG).
Who is sponsoring clinical trial NCT04624672?
This trial is sponsored by Geisinger Clinic, which has 107 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.